Is Fabino Enter overvalued or undervalued?

As of 8 October 2025, the valuation grade for Fabino Enter has moved from risky to very expensive. The company is currently overvalued based on its financial metrics. Key ratios include a PE ratio of 4.83, an EV to EBIT of 6.22, and a ROE of 3.03%. In comparison to its peers, Fabino Enter's PE ratio is significantly lower than Sun Pharma's 34.13 and Divi's Lab's 70.37, indicating that it is trading at a discount relative to these competitors despite its high valuation grade. Fabino Enter's financial performance has been disappointing, as evidenced by a year-to-date stock return of -30.09%, contrasting sharply with the Sensex's positive return of 4.65% over the same period. This underperformance, combined with its very expensive valuation grade and low profitability ratios, further supports the conclusion that the company is overvalued in the current market environment.